pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
=== 27 December === Russian Foreign Minister Sergey Lavrov stated that Ukraine must accept Moscow's peace demands: "Our proposals for the demilitarisation and denazification of the territories controlled by the regime, the elimination of threats to Russia's security emanating from there, including our new lands, are well known to the enemy. The point is simple: Fulfil them for your own good. Otherwise, the issue will be decided by the Russian army." Russia banned crude oil sales to price cap nations which includes G7, European Union, and Australia. President Putin issued a decree that ban will be effective from 1 February 2023 up to 5 months and stated that sale ban could be lifted to individuals through "specific reasons".
Platelets play an essential role in clotting. When the wall of a blood vessel is damaged, platelets adhere to the exposed surface at the site of injury and plug the gap. Simultaneous activation of the coagulation cascade results in the formation of fibrin, which reinforces the platelet plug to create a stable clot. A low platelet count, known as thrombocytopenia, may cause bleeding if severe. It can occur in individuals who are undergoing treatments that suppress the bone marrow, such as chemotherapy or radiation therapy, or taking certain drugs, such as heparin, that can induce the immune system to destroy platelets. Thrombocytopenia is a feature of many blood disorders, like acute leukaemia and aplastic anemia, as well as some autoimmune diseases. If the platelet count is extremely low, a platelet transfusion may be performed. Thrombocytosis, meaning a high platelet count, may occur in states of inflammation or trauma, as well as in iron deficiency, and the platelet count may reach exceptionally high levels in people with essential thrombocythemia, a rare blood disease. The platelet count can be reported in units of cells per microlitre of blood (/μL), 103 cells per microlitre (× 103/μL), or 109 cells per litre (× 109/L).
=== Peptide synthesis === Continuing and expanding the tradition of the University of Athens within the subject, starting from Zervas of Bergmann-Zervas carbobenzoxy method fame, Photaki initially worked on further refinement of suitable protecting groups for oligopeptide synthesis. She investigated with Zervas new types of protection such as N-protection with benzyl phosphate esters (N-phosphamide derivatives), S-protection using trityl, benzhydryl or benzoyl groups (as part of the greater effort for the synthesis of asymmetric cysteine-containing peptides), N-protection using the o-nitrophenylsulfenyl (NPS) group discovered in their Athens laboratory, or S-protection using the p-methoxycarbobenzoxy group (a modification of the Z group). With the above methodologies she embarked on the synthesis of complex polypeptides, especially fragments of enzyme active sites and peptide hormones. Some notable achievements in papers Photaki co-authored include the first synthesis of the 20-membered insulin intra-chain ring or –following her research under du Vigneaud– several previously inaccessible oxytocin analogues (e.g. 4-deamido-oxytocin) and a novel oxytocin synthesis via a different route than the du Vigneaud synthesis. In later years she also examined the preparation of biologically active atypical peptides such as Nω-arginine or lanthionine-containing peptides.
Sources: en.wikipedia.org
This use a treatment for disease was pioneered in 1890 by Emil von Behring and Shibasaburo Kitasato, who first demonstrated that the endotoxin from the infectious diseases diphtheria and tetanus could be used to prevent or cure non-immunized animals using serum transfusions from an immune animal to a susceptible one. Building on in this logic, and at the same session of the Society of Biology in Paris on February 10, 1894, Albert Calmette at the Pasteur Institute and independently Césaire Phisalix and Gabriel Bertrand at the Department of Pathology and Chemistry in the National Museum of National History in France, announced that they had achieved treatment of a vulnerable animal with serum from an immunized one both using snake venom. Calmette went on subsequently to immunize horses using venom from Indian cobras, and the resulting Serum Antivenimeux (antivenomous serum) became the first commercially available antivenom product. In 1895 Sir Thomas Fraser, Professor of Medicine at the University of Edinburgh, also produced a serum to act against cobra venom. His "antivenene" was effective in the laboratory. In 1901, Vital Brazil, working at the Instituto Butantan in São Paulo, Brazil, developed the first monovalent and polyvalent antivenoms for Central and South American Crotalus and Bothrops snakes, as well as for certain species of venomous spiders, scorpions, and frogs. In Mexico in 1905, Daniel Vergara Lope developed an antivenom against scorpion venom, by immunizing dogs. In Australia, the Commonwealth Serum Laboratories (CSL) began antivenom research in the 1920s.
== Use == Lactobacillus delbrueckii subsp. bulgaricus is commonly used alongside Streptococcus thermophilus as a starter for making yogurt. The Lb. bulgaricus 2038 strain has been used for decades for yogurt fermentation. The two species work in synergy, with L. d. bulgaricus producing amino acids from milk proteins, which are then used by S. thermophilus. This relationship is considered to be symbiotic. Both species produce lactic acid, which gives yogurt its tart flavor and acts as a preservative. The resulting decrease in pH also partially coagulates the milk proteins, such as casein, resulting in yogurt's thickness. While fermenting milk, L. d. bulgaricus produces acetaldehyde, one of the main yogurt aroma components. Some strains of L. d. bulgaricus, such as L. bulgaricus GLB44, also produce bacteriocins, which have been shown to kill undesired bacteria in vitro. The viability of Lactobacillus delbrueckii subsp. bulgaricus is extremely important in that it is necessary for it to be efficient at fermentation and to effectively keep the food products it produces from spoiling. Freeze-drying is the preferred method of preserving the viability of the cells, but not all cells survive this process. Due to its usefulness in natural fermentation processes, specifically in how it makes fermented food products out of cow's milk, it has great economic importance. Some of the biggest importers of the bacterium are Japan, the United States, and the European Union.
=== Pollution control and bioremediation === Sewage can be treated with algae, reducing the use of large amounts of toxic chemicals that would otherwise be needed. Algae can be used to capture fertilizers in runoff from farms. When subsequently harvested, the enriched algae can be used as fertilizer. Aquaria and ponds can be filtered using algae, which absorb nutrients from the water in a device called an algae scrubber, also known as an algae turf scrubber. Agricultural Research Service scientists found that 60–90% of nitrogen runoff and 70–100% of phosphorus runoff can be captured from manure effluents using a horizontal algae scrubber, also called an algal turf scrubber (ATS). Scientists developed the ATS, which consists of shallow, 30-metre (100 ft) raceways of nylon netting where algae colonies can form, and studied its efficacy for three years. They found that algae can readily be used to reduce the nutrient runoff from agricultural fields and increase the quality of water flowing into rivers, streams, and oceans. Researchers collected and dried the nutrient-rich algae from the ATS and studied its potential as an organic fertilizer. They found that cucumber and corn seedlings grew just as well using ATS organic fertilizer as they did with commercial fertilizers. Algae scrubbers, using bubbling upflow or vertical waterfall versions, are now also being used to filter aquaria and ponds. The alga Stichococcus bacillaris has been seen to colonize silicone resins used at archaeological sites; biodegrading the synthetic substance.
Sources: en.wikipedia.org
=== Sleep === Preliminary research indicates that ghrelin participates in the regulation of circadian rhythms. A review reported finding strong evidence that sleep restriction affected ghrelin or leptin levels, or energy expenditure.
Clomipramine/sildenafil (developmental code name CDFR-0812) is a combination of the tricyclic antidepressant (TCA) and serotonin–norepinephrine reuptake inhibitor (SNRI) clomipramine and the phosphodiesterase PDE5 inhibitor and erectile dysfunction drug sildenafil which is under development for the on-demand treatment of premature ejaculation. It is taken orally. The drug is under development by CTCBIO. As of October 2025, it is in phase 3 clinical trials in South Korea.
==== Singapore ==== Chick-fil-A opened a pop-up restaurant at Esplanade Mall for three days from June 26 through 28, 2024, being the first Asian country to host a Chick-fil-A pop-up. On October 17, 2024, Chick-fil-A officially announced it would be opening in Singapore in late 2025, making the first Asian country to open the brand, and would be investing US$75 million into its first restaurant in the country for 10 years. The restaurant opened on December 11, 2025.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.